Human immunodeficiency virus type 1 biological variation and coreceptor use: From concept to clinical significance

Journal of Internal Medicine

Volumn 270, Issue 6, 2011, Pages 520-531

  Fenyo E M ^a   Esbjornsson J ^b   Medstrand, P ^b   Jansson, M ^a,c  

^a Division of Medical Microbiology ^*  (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CCR5 antagonists; Coreceptor use of different HIV 1 subtypes; Envelope glycosylation and charge; Evolution of coreceptor use; HIV 1 biological phenotypes

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4;

CONFERENCE PAPER; HUMAN IMMUNODEFICIENCY VIRUS 1; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

CELL LINE; DRUG DESIGN; GLYCOSYLATION; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 81855208925     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02455.x     Document Type: Conference Paper

References (102)

1. Asjo B, Morfeldt-Manson L, Albert J et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986; 2: 660-2.
2. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
3. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240: 80-2.
4. Fenyo EM, Morfeldt-Manson L, Chiodi F et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988; 62: 4414-9.
5. Tersmette M, de Goede RE, Al BJ et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988; 62: 2026-32.
6. Tersmette M, Gruters RA, de Wolf F et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989; 63: 2118-25.
7. Koot M, Vos AH, Keet RP et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. Aids 1992; 6: 49-54.
8. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
9. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
10. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
11. Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-8.
12. Choe H, Farzan M, Sun Y et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-48.
13. Doranz BJ, Berson JF, Rucker J, Doms RW. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res 1997; 16: 15-28.
14. Fenyö E. The role of vius biological phenotype in Human Immunodeficiency Virus pathogenesis. AIDS Rev 2001; 3: 157-68.
15. Berger EA, Doms RW, Fenyo EM et al. A new classification for HIV-1. Nature 1998; 391: 240.
16. Bjorndal A, Deng H, Jansson M et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71: 7478-87.
17. Scarlatti G, Tresoldi E, Bjorndal A et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-65.
18. Malkevitch N, McDermott DH, Yi Y et al. Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5delta32) and normal human lymphoid tissue. Virology 2001; 281: 239-47.
19. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997; 94: 1925-30.
20. Loetscher P, Moser B, Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol 2000; 74: 127-80.
21. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-5.
22. Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307: 1434-40.
23. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med 2009; 265: 110-24.
24. Juno JA, Fowke KR. Clarifying the role of G protein signaling in HIV infection: new approaches to an old question. AIDS Rev 2010; 12: 164-76.
25. Yoder A, Yu D, Dong L et al. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 2008; 134: 782-92.
26. Wu Y, Yoder A, Yu D et al. Cofilin activation in peripheral CD4 T cells of HIV-1 infected patients: a pilot study. Retrovirology 2008; 5: 95.
27. Wu Y, Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 2009; 5: e1000520.
28. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994; 32: 364-70.
29. Koot M, Keet IP, Vos AH et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-8.
30. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968-74.
31. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR et al. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med 1997; 185: 621-8.
32. Spijkerman IJ, Koot M, Prins M et al. Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. Aids 1995; 9: 1085-92.
33. Tscherning C, Alaeus A, Fredriksson R et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998; 241: 181-8.
34. Zhang L, Huang Y, He T, Cao Y, Ho DD. HIV-1 subtype and second-receptor use. Nature 1996; 383: 768.
35. Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 359: 1965-6.
36. Abebe A, Demissie D, Goudsmit J et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Aids 1999; 13: 1305-11.
37. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, Fenyo EM. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999; 15: 647-53.
38. Cilliers T, Nhlapo J, Coetzer M et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003; 77: 4449-56.
39. Kaleebu P, Nankya IL, Yirrell DL et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45: 28-33.
40. Yu XF, Wang Z, Beyrer C et al. Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. J Virol 1995; 69: 4649-55.
41. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, Papathanasopoulos MA. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. Aids 2008; 22: 896-9.
42. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005; 13: 269-77.
43. Davenport MP, Zaunders JJ, Hazenberg MD, Schuitemaker H, Van Rij RP. Cell turnover and cell tropism in HIV-1 infection. Trends Microbiol 2002; 10: 275-8.
44. Hazenberg MD, Stuart JW, Otto SA et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-55.
45. Mild M, Esbjornsson J, Fenyo EM, Medstrand P. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J Virol 2007; 81: 3369-76.
46. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004; 78: 5205-15.
47. Hunt G, Tiemessen CT. Occurrence of additional NF-kappaB-binding motifs in the long terminal repeat region of South African HIV type 1 subtype C isolates. AIDS Res Hum Retroviruses 2000; 16: 305-6.
48. van Harmelen J, Williamson C, Kim B et al. Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses 2001; 17: 1527-31.
49. Ball SC, Abraha A, Collins KR et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003; 77: 1021-38.
50. Tebit DM, Nankaya I, Arts EJ, Gao Y. HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Review 2007; 9: 75-87.
51. Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr 2011; 56: 9-15.
52. Konings FA, Burda ST, Urbanski MM, Zhong P, Nadas A, Nyambi PN. Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02_AG (CRF02_AG) has a higher in vitro replicative capacity than its parental subtypes A and G. J Med Virol 2006; 78: 523-34.
53. Njai HF, Gali Y, Vanham G et al. The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006; 3: 40.
54. Troyer RM, Collins KR, Abraha A et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005; 79: 9006-18.
55. Bunnik EM, Euler Z, Welkers MR et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med 2010; 16: 995-7.
56. Kawashima Y, Pfafferott K, Frater J et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458: 641-5.
57. Esbjornsson J, Mansson F, Martinez-Arias W et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa. Retrovirology 2010; 7: 23.
58. Quinones-Mateu ME, Ball SC, Marozsan AJ et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74: 9222-33.
59. Shankarappa R, Margolick JB, Gange SJ et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73: 10489-502.
60. de Roda Husman AM, van Rij RP, Blaak H, Broersen S, Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis 1999; 180: 1106-15.
61. Jansson M, Backstrom E, Bjorndal A et al. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J Hum Virol 1999; 2: 325-38.
62. Borggren M, Repits J, Kuylenstierna C et al. Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology 2008; 5: 28.
63. Gray L, Sterjovski J, Churchill M et al. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 2005; 337: 384-98.
64. Jansson M, Popovic M, Karlsson A et al. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci U S A 1996; 93: 15382-7.
65. Karlsson I, Antonsson L, Shi Y et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004; 78: 11807-15.
66. Koning FA, Kwa D, Boeser-Nunnink B et al. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis 2003; 188: 864-72.
67. Kwa D, Vingerhoed J, Boeser B, Schuitemaker H. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis 2003; 187: 1397-403.
68. Mild M, Kvist A, Esbjornsson J, Karlsson I, Fenyo EM, Medstrand P. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol 2010; 10: 356-64.
69. Repits J, Oberg M, Esbjornsson J et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005; 86: 2859-69.
70. Repits J, Sterjovski J, Badia-Martinez D et al. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 2008; 379: 125-34.
71. Sterjovski J, Churchill MJ, Ellett A et al. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007; 4: 89.
72. Sterjovski J, Roche M, Churchill MJ et al. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology 2010; 404: 269-78.
73. Wade J, Sterjovski J, Gray L et al. Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology 2010; 396: 246-55.
74. Duenas-Decamp MJ, Peters PJ, Repik A et al. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Future Virol 2010; 5: 435-51.
75. Karlsson I, Grivel JC, Chen SS et al. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. J Virol 2005; 79: 11151-60.
76. Antonsson L, Boketoft A, Garzino-Demo A, Olde B, Owman C. Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. Aids 2003; 17: 2571-9.
77. Karlsson I, Antonsson L, Shi Y et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. Aids 2003; 17: 2561-9.
78. Zhou N, Luo Z, Hall JW, Luo J, Han X, Huang Z. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Eur J Immunol 2000; 30: 164-73.
79. Cavarelli M, Karlsson I, Ripamonti C, Plebani A, Fenyo EM, Scarlatti G. Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children. Aids 2010; 24: 2527-33.
80. Cavarelli M, Karlsson I, Zanchetta M et al. HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. PLoS ONE 2008; 3: e3292.
81. Karlsson U, Antonsson L, Repits J et al. Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates. AIDS Res Hum Retroviruses 2009; 25: 1297-305.
82. Borggren M, Repits J, Sterjovski J et al. Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS ONE 2011; 6: e20135.
83. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008; 82: 7932-41.
84. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nature reviews. Immunology 2006; 6: 859-68.
85. van Montfort T, Nabatov AA, Geijtenbeek TB, Pollakis G, Paxton WA. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J Immunol 2007; 178: 3177-85.
86. Seclen E, Soriano V, Del Mar Gonzalez M, Gonzalez-Lahoz J, Poveda E. Severe immune suppression in patients infected with R5-Tropic HIV-1 strains is associated with increased gp120 net charge at variable regions. AIDS Res Hum Retroviruses 2011; 27: 965-67.
87. Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 2004; 86: 1234-42.
88. Atchison RE, Gosling J, Monteclaro FS et al. Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science 1996; 274: 1924-6.
89. Rucker J, Samson M, Doranz BJ et al. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 1996; 87: 437-46.
90. Doranz BJ, Lu ZH, Rucker J et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997; 71: 6305-14.
91. Lee B, Sharron M, Blanpain C et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999; 274: 9617-26.
92. Edinger AL, Amedee A, Miller K et al. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci U S A 1997; 94: 4005-10.
93. Kondru R, Zhang J, Ji C et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008; 73: 789-800.
94. MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 47: 236-41.
95. Perry CM. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 2010; 70: 1189-213.
96. Fatkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionN Engl J Med 2008; 359: 1442-55.
97. Symons J, van Lelyveld SF, Hoepelman AI et al. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. J Antimicrob Chemother 2010; 66: 890-5.
98. Moore JP, Kuritzkes DR. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009; 4: 118-24.
99. Westby M. Resistance to CCR5 antagonists. Curr Opin HIV AIDS 2007; 2: 137-44.
100. Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 2009; 5: e1000548.
101. Ogert RA, Ba L, Hou Y et al. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol 2009; 83: 12151-63.
102. Tilton JC, Wilen CB, Didigu CA et al. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 2010; 84: 10863-76.